key: cord-0770781-g5nvv8ys
authors: Nerenz, Robert D.; Hubbard, Jacqueline A.; Cervinski, Mark A.
title: Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance
date: 2021-06-23
journal: Adv. Mol. Pathol.
DOI: 10.1016/j.yamp.2021.06.008
sha: abe9361deef31a7bfd5679804f5d72141fcdebd5
doc_id: 770781
cord_uid: g5nvv8ys

This review article highlights the essential role of laboratory medicine in the global response to SARS-CoV-2 through the implementation rapid and accurate test methods. We discuss the design and performance characteristics of commercially available antibody platforms, antibody response after natural infection and vaccination, and the use of antigen testing as a diagnostic tool. Taken together, we emphasize the necessity for rapid and reliable laboratory testing to detect, contain and eradicate SARS-CoV-2.

• SARS-CoV-2 antigen tests offer short turnaround time and high specificity but the lower sensitivity relative to nucleic acid testing increases the risk of further transmission by patients with false negative antigen test results.

• While numerous SARS-CoV-2 antibody detection methods exist, the lack of harmonization and correlation with neutralizing antibodies limits their clinical utility.

• SARS-CoV-2 antibody titers are higher after vaccination than after a natural infection, but antibody longevity and the frequency at which vaccine re-immunization will be needed are still unknown.

This review article highlights the essential role of laboratory medicine in the global response to SARS-CoV-2 through the implementation rapid and accurate test methods. We discuss the design and performance characteristics of commercially available antibody platforms, antibody response after natural infection and vaccination, and the use of antigen testing as a diagnostic tool. Taken together, we emphasize the necessity for rapid and reliable laboratory testing to detect, contain and eradicate SARS-CoV-2.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified as the cause of the COVID-19 global pandemic, is a single stranded RNA virus belonging to the coronavirus family. It consists of structural spike proteins that interact with angiotensin-converting enzyme 2 (ACE2) receptors to infect host cells, nucleocapsid protein that encapsulates the RNA, and envelope protein that surrounds the nucleocapsid. 1 Commercially available antibody assays have predominantly been developed to target antibodies to either the spike or nucelocapsid proteins. While the nucleocapsid protein is highly conserved and less susceptible to genetic variation, the spike protein is the target of neutralizing antibodies, which are hypothesized to correlate with immunity. [2] [3] [4] [5] Despite public health efforts to encourage masking, social distancing, and surveillance testing, the SARS-CoV-2 virus continued to spread at an alarming rate. As a result, significant effort was dedicated to the development of vaccines against SARS-CoV-2. After rapid development and deployment, several manufacturers began clinical trials on their vaccine within just months of the sequencing of the SARS-CoV-2 virus. 6 All vaccines available at the time of this publication target the spike protein, and immunocompetent individuals who receive the vaccine develop only anti-spike antibodies. In contrast, after a natural infection, both anti-spike and antinucleocapsid antibodies are detectable. Additional longitudinal studies are required to determine the longevity of antibodies after a natural infection or vaccination, as this currently remains unknown.

The gold standard for diagnosing a SARS-CoV-2 infection is nucleic acid amplification testing with throat or nasopharayngeal swabs. 6 However, difficulty of sample collection, slow turnaround time due to batch mode testing and instrument shortages, and supply chain shortages for reagents and consumables limited the ability to produce quick diagnostic results in many laboratories. As a result, several manufacturers developed rapid antigen-based assays for the diagnosis of SARS-CoV-2. While these offer several logistical advantages, including rapid identification of infected individuals and ease of implementation in a non-laboratory setting, antigen testing is considered less sensitive than molecular diagnostic techniques. Furthermore, the performance may vary considerably depending on whether it is used on symptomatic individuals, or whether it is used as a screening tool for asymptomatic individuals. 7 The essential role of rapid and accurate clinical laboratory testing has been highlighted during the SARS-CoV-2 global pandemic. In this review, we discuss the design and performance characteristics of commercially available antibody platforms. We then review antibody response after natural infection and after vaccination, with an emphasis on development of the three vaccines currently authorized for use in the United States (Pfizer-BioNtech, Moderna, and Janssen Biotech, Inc.). Finally, we consider the use of antigen testing as an alternative diagnostic tool to nucleic acid testing. Taken together, we emphasize the essential contributions of laboratory medicine professionals in the global effort to detect, contain and eradicate SARS-CoV-2.

J o u r n a l P r e -p r o o f

The appearance of and subsequent spread of the novel coronavirus causing SARS-CoV-2 has challenged healthcare systems on a global scale. The accurate and rapid detection of the SARS-CoV-2 virus has propelled the laboratory community, particularly molecular pathology and microbiology laboratories, into the spotlight. As the pandemic has grown and evolved, new assay modalities focusing on the human host's adaptive immune response to SARS-CoV-2 have become available.

By April of 2020 the United States Food and Drug Administration (FDA) began to grant emergency use authorization (EUA) for a limited number of immunoassays designed to detect the presence of antibodies specific to the SARS-CoV-2 virus. 8 Importantly these serology tests are not designed to detect current infection with the SARS-CoV-2 virus, as immunoglobulins specific to viral proteins may not have developed in the time between infection and symptom onset. Consequently, diagnosis of active SARS-CoV-2 infection is still best achieved using nucleic acid techniques, or via specific detection of SARS-CoV-2 viral proteins.

Despite these limitations, numerous in vitro diagnostic (IVD) companies and clinical laboratories devoted considerable resources to develop serologic methods to detect SARS-CoV-2 specific IgM and IgG antibodies with the expectation that these assays may fill an unmet laboratory testing need.

At the time of this report, 52 assays have attained FDA EUA, with the exclusion of point-of-care lateral flow immunoassays and laboratory developed tests. These EUA SARS-CoV-2 serology assays fall into two general methodological categories, antibody isotype specific, and nonspecific or total immunoglobulin assays ( Figure 1 , Table 1 ). Within the isotype non-specific and specific categories there are also methodological differences in regards to the antigen immobilization scheme used, with assays employing microparticle or paramagnetic/magnetic particles predominating over the more traditional microwell or plate based formats.

Given the close homology of SARS-CoV-2 proteins with those of other coronaviruses, including the SARS-CoV-1 virus that caused the more limited SARS outbreak between the years of 2002 -2004, there was concern that serology assays would be subject to frequent false positive results due to prior exposure to related human coronaviruses. The spike proteins of the related betacorona viruses infecting humans display varying degrees of sequence homology (SARS-CoV-The low cross-reactivity for spike proteins from human betacoronaviruses was a welcomed discovery, and this also extends to assays targeting the SARS-CoV-2 nucleocapsid protein.

Although the nucleocapsid protein of the closely related SARS-CoV-1 virus and MERS-CoV display homology with SARS-CoV-2, the amino acid sequence differences between SARS-CoV-2 nucleocapsid and the other endemic coronaviruses 11-13 are sufficient to limit predicted crossreactivity.

Data from subsequent publications examining available serological assays from IVD manufacturers has confirmed these predictions. These publications demonstrated very low false-positive rates across multiple test manufacturers and platforms by testing sera from either well characterized SARS-CoV-2 PCR-negative patients, or samples collected prior to December 2019, the generally accepted date associated with SARS-CoV-2 spread. [14] [15] [16] [17] These manuscripts also characterized the persistence of antibody development up to 200 days post positive PCR result in cohorts of patients following PCR-confirmed infection with SARS-CoV-2. 15 When the data of these publications are normalized to the number of days postpositive SARS-CoV-2 PCR, the IVD platforms examined ( Table 2 ) display sensitivities ranging from 75 -99%. [14] [15] [16] [17] Further, these manuscripts also provide indirect evidence as to the clear lack of utility in diagnosing active SARS-CoV-2 infection. The sensitivity for detecting a specific antibody response at approximately 7 days post-positive PCR ranged from 58% -96%. This wide range in J o u r n a l P r e -p r o o f 8 sensitivity is surprising particularly in that the same platform in one publication displayed a sensitivity as low as 59% between 3 and 7 days post-positive PCR, while in another the sensitivity was reported as 96% for samples collected < 7 days post-positive PCR. 15, 17 One possible explanation for the discrepancy in sensitivity is a difference in time between symptom onset and performance of the PCR test.

Of the numerous hurdles limiting the clinical utility of SARS-CoV-2 serology testing are the lack of assay harmonization or international standardization, as well as the currently sparse data correlating serology antibody result to neutralizing antibody titer. In two recent publications, this question of correlation of serology result to neutralizing titer was examined. 18, 19 Both publications demonstrated that a positive correlation exists between automated serology assay signal and neutralizing antibody titer. The limitation of these studies are that neither manuscript contains data from quantitative or semiquantitative serology assays, but rather rely on the ratio of assay signal to a positive calibrator or cut-off signal.

In the publication by Tang MS, et al., the authors demonstrate that at a neutralizing titer of 1:64, that the positive percent agreement (PPA) for the Abbott, Roche, and Euroimmun assays are 96%, 100%, and 92%, respectively, when utilizing the manufacturers' specified positive ratio thresholds. 19 At the manufacturer specified positive thresholds the negative predictive agreement (NPA) of the three were, 50%, 70%, and 47%. The authors also calculated serology J o u r n a l P r e -p r o o f assay specific ideal ratios for the three assays which slightly decreased the PPA, but increased the NPA for each assay.

In the manuscript by Suhandynata RT, et al., examined the PPA between three commercially available serology assays as well as to a neutralization assay titer of 50. 20 Samples testing positive on both the Diazyme and Roche assays, or Diazyme and Abbott assays had PPA values of 79.2% and 78.4%, respectively. Unfortunately, due to the methodological differences between the two manuscripts, a direct comparison of data is not possible.

These early studies correlating automated serology assay signal to neutralization titer are encouraging, however additional studies utilizing semiquantitative or quantitative assays are needed to determine if a universal threshold indicating immunity is possible.

Early publications supported a classic viral response pattern after infection with SARS-CoV-2. 21, 22 In this model, IgM antibodies are first detected within one week after infection, and IgG antibodies develop several days after that. Instead, IgG antibodies to SARS-CoV-2 appear before or at the same time as IgM antibodies. 23, 24 In the classic viral response model, IgG antibodies were predicted to increase over time, peak around 1 month after an infection, and remain detectable for 1-6 years. 22 Although antibody longevity may not be confirmed for several years, J o u r n a l P r e -p r o o f many research groups have investigated the time to initial antibody detection and ongoing studies are monitoring antibody response over time.

Determining antibody seroconversion rates after a SARS-CoV-2 infection can be difficult because the exact day of infection is often unknown. The window period between infection and the presence of detectable antibodies ranged from less than 4 days to several weeks after a confirmed infection. [23] [24] [25] [26] [27] [28] Seroconversion kinetics may also depend on disease severity. People with mild or asymptomatic infections generally had a weaker immune response than those with symptomatic or severe infection. 23, 27 However, it has also been reported that asymptomatic patients seroconvert more quickly compared to those are who are symptomatic. 28 Interindividual variation combined with the novelty of the SARS-CoV-2 virus have contributed to an incomplete understanding of the humoral response.

As described above, the antibody response pattern over time varies widely with the analytical platform being used. 25, [29] [30] [31] However, differing antibody trends are at least partially attributed to whether anti-nucleocapsid or anti-spike antibodies are being monitored. Previous reports have demonstrated that while nucleocapsid antibodies continue to rise over time, antibodies to the spike protein begin to decline within one to four months after symptom onset. 30, 32, 33 This phenomenon has been observed on several different test platforms. Despite this, antibodies to both the spike and nucleocapsid antibodies remain detectable for several months after infection. Future studies should continue to monitor the longevity of antibodies to both the nucleocapsid and spike proteins after natural infection.

Neutralizing antibodies can block infection by the SARS-CoV-2 virus. Because the spike protein engages ACE2 receptors to initiate infection, antibodies to the spike protein have been theorized to correlate with antibody neutralization. 5, 20, 34 After a natural infection, spike antibodies were moderately associated (R 2 = 0.46) with neutralizing antibody titers but suffered from a poor negative percent agreement. 34 Interestingly, the correlation between antinucleocapsid antibodies with neutralizing antibodies was assay dependent, but ranged from a coefficient of determination of 0.29 to 0.47. After vaccination, antibodies to the spike protein also exhibited a moderate association (R 2 = 0.39) with neutralizing titers. 20 Current vaccinations only elicit a humoral response against the spike protein of SARS-CoV-2 and therefore would not have any association with nucelocapsid antibody response.

As a result of the COVID-19 global pandemic, vaccine development through multinational collaborations has occurred at an unprecedented rate. Antibody response after vaccination will be an important consideration when establishing re-immunization intervals. At the time of this publication, all vaccines currently granted EUA by the world health organization (WHO) target available vaccines result in antibody titers that exceed those seen after a natural infection. [36] [37] [38] While this robust response is promising, antibody longevity after vaccination remains unknown and may vary with vaccine technology. Understanding how each vaccine works will be an important consideration when monitoring antibody titers to determine re-immunization frequency.

After the COVID-19 outbreak in December 2019, the entire genomic sequence of SARS-CoV-2 was published in January 2020. By March 2020, vaccines were developed, shipped to appropriate testing sites, and early phase clinical and pre-clinical trials were underway. As of As more vaccines are developed, it will become increasingly important to monitor reactogenicity and immunogenicity in addition to efficacy. Differences in immune response and frequency of adverse events may help personalize vaccine selection, with potent vaccines J o u r n a l P r e -p r o o f preferred in individuals who may produce a suboptimal immune response, and single dose vaccines preferred for those who are prone to adverse reactions after vaccination.

Nucleic acid amplification tests detecting the presence of SARS-CoV-2 RNA are considered the gold standard for diagnosis of symptomatic patients by the Centers for Disease Control and Prevention. 50 Although these assays offer optimal sensitivity and specificity, their Analytical sensitivity has been estimated to fall between 4-8x10 4 copies/swab, roughly approximating a generic RT-PCR cycle threshold (C T ) value of 29-30. 51 One study compared the performance of the BinaxNOW lateral flow antigen test to the Thermo Fisher TaqPath COVID-19 Combo kit in 2,645 asymptomatic students at the University of Utah using two concurrent nasal swabs self-collected by study participants under the supervision of trained, non-medical personnel. 52 Antigen testing was performed at the collection site by trained non-medical personnel while RT-PCR testing was performed at a reference laboratory.

SARS-CoV-2 RNA was detected by RT-PCR in 1.7% of the study participants. Relative to RT-PCR, the BinaxNOW antigen test demonstrated a sensitivity of 53.3% and a specificity of 100%.

A second study summarized the performance of the BinaxNOW antigen device relative to the CRSP SARS-CoV-2 RT-PCR assay in specimens collected at a drive-through community testing site in Massachusetts. 7 Two nasal swabs were collected from each participant by trained medical personnel, with one swab used to perform BinaxNOW testing on-site in a dedicated testing tent while the other swab was sent to an off-site reference laboratory for RT-PCR testing. In this study population, 974/1,380 (71%) of adults and 829/928 (89%) were asymptomatic. Among symptomatic participants, the BinaxNOW device demonstrated a sensitivity of 96.5% in adults and 84.6% in children (ages 7-17 years) and a specificity of 100% in J o u r n a l P r e -p r o o f both age groups. Among asymptomatic participants, sensitivity was 70.2% in adults and 65.5% in children while specificity was 99.6% in adults and 99.0% in children.

A third study compared the BinaxNOW antigen device to either the CDC or Fosun SARS-CoV-2 RT-PCR assay using concurrently collected nasal (antigen) and nasopharyngeal (RT-PCR) samples from participants in two community testing centers in Pima County, AZ. 53 Antigen testing was asymptomatic. In symptomatic participants presenting within seven days of symptom onset, sensitivity and specificity of the BinaxNOW device were 71.1% and 100%, respectively. In asymptomatic participants, sensitivity and specificity were 35.8% and 99.8%, respectively.

The Quidel Sofia SARS-CoV-2 lateral flow antigen assay was granted EUA in May 2020 and is intended for use in symptomatic individuals within five days of symptom onset. Results are introduced into a device reader that reports digital results as positive or negative between 15 and 30 minutes.

One study performed on two college campuses in Wisconsin evaluated the performance of the Sofia antigen device to either the CDC or Thermo Fisher TaqPath COVID-19 Combo RT-PCR assays. 54 At University A, all persons tested for screening or diagnostic purposes were eligible to participate in the study. At University B, participation was limited to only those quarantined following a known COVID-19 exposure. Two concurrent nasal swabs were collected from participants in both groups (medical personnel collect at University A, self-collect at University A second study with two parts evaluated the BD Veritor relative to the Lyra RT-PCR assay in concurrently collected nasal (antigen) and naso-or oropharyngeal swabs (RT-PCR) in 251 symptomatic individuals within seven days of symptom onset presenting to 21 geographically diverse study locations (Part 1). 58 RT-PCR testing was performed at a commercial reference laboratory while antigen testing was performed at a laboratory operated by the device manufacturer. SARS-CoV-2 RNA was detected in 38/251 (15.1%) of Part 1 study participants. In participants with two or more symptoms, sensitivity, specificity, PPV and NPV were 88%, 100%, 100% and 97.3%, respectively. In participants with one symptom, values were 67%, 100%, 100% and 97.7%, respectively. In Part 2, concurrently collected nasal swabs from 377 symptomatic participants at five study sites were tested at an off-site commercial reference laboratory on the BD Veritor and Sofia devices according to the manufacturer's instructions. Using the Sofia J o u r n a l P r e -p r o o f device as the reference method, the BD Veritor demonstrated a sensitivity and specificity of 97.4% and 98.1%, respectively.

Many have advocated for the implementation of serial SARS-CoV-2 antigen testing to facilitate rapid identification of infected individuals and permit timely self-quarantine to prevent further viral spread. Although antigen testing is consistently less sensitive than molecular diagnostic techniques, the short turnaround time and capacity for repeated testing may support efforts at viral containment more effectively than single sample nucleic acid testing with a long turnaround time. To date, relatively few studies have tested this hypothesis.

One publication describing the implementation of the Sofia antigen device in routine monitoring of intercollegiate athletes documented two separate SARS-CoV-2 outbreaks attributed to false negative antigen test results. 59 In outbreak A, 32 confirmed cases were traced to contact during a team meeting with a single infectious individual whose antigen test result was negative on the morning of the meeting. Viral RNA sequences were closely related, supporting transmission from a single individual to the other team members. The authors note that viral transmission was not interrupted until the implementation of RT-PCR testing, which led to the identification of an additional 21 confirmed SARS-CoV-2 infections, 18 of which were not detected by concurrent antigen testing. In outbreak B, 12 confirmed cases were documented in two teams competing against each other, all of whose participants received J o u r n a l P r e -p r o o f negative antigen test results on the day of competition. Viral RNA sequences were closely related and distinctly different from strains circulating in one of the teams' communities, supporting transmission from one team to the other.

To reduce rates of viral transmission, SARS-CoV-2 diagnostic test methods must be analytically accurate, accessible, and reported in a timely and effective manner. Antigen methods generate rapid results and their high specificity and PPV allows SARS-CoV-2-positive individuals to quickly self-isolate, minimizing the risk of further viral spread. However, the lower sensitivity of antigen methods relative to nucleic acid test methods increases the likelihood of further transmission in high-interaction environments by individuals with false negative antigen results. With this limitation in mind, confirmation of negative antigen results by nucleic acid testing is recommended, particularly in patient populations with a high disease prevalence.

In addition to the test method used, the environment in which testing is performed is a primary determinant of the effectiveness of SARS-CoV-2 testing efforts. The majority of studies evaluating antigen test performance described dedicated testing spaces staffed by trained operators with no other competing responsibilities. Little is known about how antigen devices perform when implemented in patient care settings with testing performed by clinical personnel who are also actively caring for patients. The limited available data using the BD Veritor device suggest improved performance in a controlled laboratory setting relative to an J o u r n a l P r e -p r o o f active patient care environment. 57, 58 However, this observation is complicated by differences in reference method and disease prevalence in the study populations. 

Epidemiology, virology, and clinical features of severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2

Coronavirus Disease-19)

The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development

Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle

Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients

COVID-19-neutralizing antibodies predict disease severity and survival

Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection

Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease

Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies

A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays

Multi-Platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19

Clinical Performance of Two SARS-CoV-2 Serologic Assays

Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2

Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays

SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. medRxiv

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Antibody responses to SARS-CoV-2 in patients with COVID-19

Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. The Journal of Applied Laboratory Medicine

Multi-platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medRxiv

Clinical Performance of Two SARS-CoV-2 Serologic Assays

A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays

Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays

COVID-19 vaccine tracker and landscape

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Vaccines and Related Biological Products Advisory Committee Meeting December

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Announcement

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Vaccines and Related Biological Products Advisory Committee Meeting

Analytical Sensitivity of the Abbott BinaxNOW COVID-19 Ag Card

Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting

Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites

Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses -Wisconsin

Diagnostic Performance of an Antigen Test with RT-PCR for the Detection of SARS-CoV-2 in a Hospital Setting

Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients

Evaluation of Performance of the BD Veritor SARS-CoV-2

Chromatographic Immunoassay Test in Patients with Symptoms of COVID-19

Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test

SARS-CoV-2 transmission in intercollegiate athletics not fully mitigated with daily antigen testing